



Brenus Pharma announces its international Scientific Committee



LYON, (FRANCE), June 7th, 2023, - Following the [American Society of Clinical Oncology's](#), Annual Meeting, where Brenus' innovative approach and promising preclinical results were featured in the abstract section "Treatment to Follow"¹, the company highlighted its international scientific committee.

This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel treatments is supporting Brenus' scientific developments of the STC² platform pipeline in solid tumors and its first candidate, STC-1010 targeting colorectal cancer.

The committee combined a total of over 1,700 internationally peer-reviewed articles and prestigious awards in the field:

Pr François GHIRINGHELLI MD, PhD. Pr of Oncology – Head of "Cancer and adaptative immune response" INSERM, [CGFL](#)³, Dijon. (FR) [Head of the Board](#)

Pr Ahmad AWADA MD, PhD. Pr of Oncology – Head of Oncology medicine Dept. at [Jules Bordet Institute-HUB](#), Brussel. (BE) & Board member of [Oncodistinct clinical and translational research network](#), [ESMO](#)⁴ [active member](#). Expertise in new drugs development.

Pr Alexander EGGERMONT MD, PhD. Pr of Oncology – Head of Clinical & Translational Immunotherapies. [UMC](#)⁵, Utrecht (NL); Chief Scientific Officer. [Pediatric oncology center Princessa Maxima](#), Utrecht. (NL)

Pr. Antoine ITALIANO MD, PhD. Pr of Oncology – Head of Early phase trials units; Head of Precision medicine new program. [Gustave Roussy](#), Cancer Campus Grand Paris (FR) ; [Bergonié Institute](#), UNICANCER Nouvelle-Aquitaine, Bordeaux. (FR)

Pr. Ignacio MELERO MD, PhD. Pr of Immunology – Head of translational immunotherapy research. [CIMA](#)⁶, Navarra. (SP)

Pr Marck YARCHOAN MD. Associate Pr. of Medical Oncology at The Sidney Kimmel Comprehensive Cancer Center. [Johns Hopkins](#), Baltimore. (USA)

"Brenus' innovative approach is supported by a specialized scientific advisory board which improves the strategy of basic and translational science development and provides fruitful help for clinical development". **François GHIRINGHELLI**, [Head of the board](#), "This strategy has proven to be highly effective, producing tangible results thus far. With the expertise and guidance of the advisory board, Brenus has successfully advanced its developments into clinical trials and is poised to extend its groundbreaking work to other domains, promising continued advancements and breakthroughs."

"Brenus is honored to have the support & guidance of such professionals in the field. Their expertise will be instrumental in driving the first-in-human study forward in 2024, and advancing the company's mission to change a paradigm in oncology." **Benoit PINTEUR**, [Co-founder & CSO](#).

¹ « Efficacy of STC-1010, a new allogeneic cancer vaccine in colorectal cancer models" [J Clin Oncol 41, 2023 \(suppl 16; abstr e14661\)](#).

² Stimulated-Tumor-Cells

³ Centre de lutte contre le cancer Georges François Leclerc

⁴ European Society for Medical Oncology

⁵ University MC

⁶ Centro de Investigación Medical Aplicada

ABOUT BRENUS

Brenus Pharma is developing first in class tumor-antigens focus immunotherapies for solid tumors treatment. Brenus has developed STC (Stimulated Tumor Cells), a technology platform mimicking relapsing conditions and enabling the education of patients' immune system, to fight against the resistance mechanisms of tumor cells.

For further information: www.brenus-pharma.com

CONTACT BRENUS

Marion Brun

Communication Manager

contact@brenus-pharma.com

+ 33 (0)7 87 76 87 72